Probiotics for chronic intestinal disorders

American Journal of Gastroenterology

Volumn 98, Issue 3, 2003, Pages 520-521

  Guslandi, Mario ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; PROBIOTIC AGENT;

ABDOMINAL PAIN; BACTERIAL STRAIN; BIFIDOBACTERIUM; CHRONIC DISEASE; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; EDITORIAL; ENTERITIS; ENTEROCOCCUS; ENTEROPATHY; ESCHERICHIA COLI; GASTROINTESTINAL TRACT; HUMAN; ILEITIS; IMMUNOSTIMULATION; INFLAMMATION; INTESTINE EPITHELIUM; INTESTINE FLORA; INTESTINE MUCOSA; INTESTINE SECRETION; IRRITABLE COLON; LACTOBACILLUS; LACTOBACILLUS PLANTARUM; MICROBIAL ACTIVITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REMISSION; SACCHAROMYCES BOULARDII; STREPTOCOCCUS; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 0037343885     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07307.x     Document Type: Editorial

References (20)

1. Hamilton-Miller JMT, Shah S, Winkler JT. Public health issues arising from microbiological and labelling quality of foods and supplements containing probiotic organisms. Public Health Nutr 1999;2:223-9.
2. Saavedra J. Probiotics and infectious diarrhea. Am J Gastroenterol 2000;95(suppl 1):S16-8.
3. Cremonini F, Di Caro S, Nista EC, et al. Meta-analysis: The effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002;16:1461-7.
4. Shanahan F. Probiotics and inflammatory bowel disease: Is there a scientific rationale? Inflamm Bowel Dis 2000;6:107-15.
5. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
6. Giaffer MH, Holdsworth CD, Duerden BI. Virulence properties of Escherichia coli isolated from patients with inflammatory bowel disease. Gut 1992;33:646-50.
7. Isolauri E, Kirjavainen PV, Salminen S. Probiotics: A role in the treatment of intestinal infection and inflammation? Gut 2002;50(suppl III):iii54-6.
8. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut 2001;48:132-5.
9. Malin M, Soumailainen H, Saxelin M, et al. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996;40:137-45.
10. Hamilton-Miller JMT. A review of clinical trials of probiotics in the management of inflammatory bowel disease. Infect Dis Rev 2001;3:83-7.
11. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:835-8.
12. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic ESCHERICHIA COLI versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet 1999; 354:635-9.
13. Guslandi M, Mezzi G, Siorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-4.
14. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-9.
15. Maxwell PR, Kumar ERD, Mendall MA. Antibiotics increase functional abdominal symptoms. Am J Gastroenterol 2002;97: 104-8.
16. Rodriguez LA, Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: A cohort study. Br Med J 1999;318:565-7.
17. Collins SM, Piche T, Rampal P. The putative role of inflammation in the irritable bowel syndrome. Gut 2001;49:743-5.
18. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind, placebo-controlled crossover study. Dig Liver Dis 2000;32: 302-4.
19. Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-8.
20. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001;13:1135-6.